EIF2AK3 and neoplasm: Moreover, an in vivo study demonstrated that PERK inhibitors increased tumor control and extended survival in combination with anti-PD-1 therapy [54], indicating that novel drugs targeting ER stress-related pathways might reverse the immunosuppressive TME and enhance the efficacy of immunotherapy.